Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics - PubMed (original) (raw)
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics
K Virtaneva et al. Proc Natl Acad Sci U S A. 2001.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous group of diseases. Normal cytogenetics (CN) constitutes the single largest group, while trisomy 8 (+8) as a sole abnormality is the most frequent trisomy. How trisomy contributes to tumorigenesis is unknown. We used oligonucleotide-based DNA microarrays to study global gene expression in AML+8 patients with +8 as the sole chromosomal abnormality and AML-CN patients. CD34(+) cells purified from normal bone marrow (BM) were also analyzed as a representative heterogeneous population of stem and progenitor cells. Expression patterns of AML patients were clearly distinct from those of CD34(+) cells of normal individuals. We show that AML+8 blasts overexpress genes on chromosome 8, estimated at 32% on average, suggesting gene-dosage effects underlying AML+8. Systematic analysis by cellular function indicated up-regulation of genes involved in cell adhesion in both groups of AML compared with CD34(+) blasts from normal individuals. Perhaps most interestingly, apoptosis-regulating genes were significantly down-regulated in AML+8 compared with AML-CN. We conclude that the clinical and cytogenetic heterogeneity of AML is due to fundamental biological differences.
Figures
Figure 1
(A) Scatter plots of the log-intensity values for the 6,606 unique genes assayed with the HuGeneFL array. The intensity values were scaled and averaged over each of three groups: AML+8, AML-CN, and CD34+ cells. (B) Dendrogram from two-way hierarchical cluster analysis of 1,959 genes passing a variation filter generated by using the programs
cluster
and T
ree
V
iew
(19). See also Fig. 5, which is published as supplemental data on the PNAS web site,
.
Figure 2
(A) Genes distinguishing AML and CD34+ samples. Expression profiles for the 30 most up-regulated (left, AML↑, from highest to lower) and down-regulated (right, AML↓, from lowest to higher) genes between AML and CD34+ samples. Normalized intensities are presented for each gene as standard deviations of log intensity above the mean (red) and below the mean (blue) across samples. Similarly generated data for genes distinguishing AML+8 and AML-CN are shown in Fig. 6, which is published as supplemental data on the PNAS web site at
. (B) Coordinate plot obtained by averaging the unit normal deviates for genes in A that were down-regulated (coordinate 1) and up-regulated (coordinate 2) in AML vs. CD34+. Cross-validation revealed perfect class prediction based on this simple rule. (C) The corresponding analyses for the most significantly dysregulated genes in AML+8 vs. AML-CN. Genes are identified by their GenBank accession number and symbol. Preliminary symbols are indicated in parentheses. Genes on chromosome 8 are highlighted (red).
Figure 3
(Left) AML+8 samples exhibit higher expression for genes on chromosome 8 than do AML-CN samples. The average expression levels for genes by chromosome in AML+8 relative to AML-CN are shown. (Right) The increased expression of genes on chromosome 8 as a function of chromosomal location. Of the 169 genes with a specific localization on the integrated radiation hybrid map of chromosome 8, 42 were expressed in a majority of AML samples. For these, the intensities in the AML+8 group are expressed as a percentage of the intensities in the AML-CN group. For comparison, the results for chromosome 1, which shows no gene dosage effect, are presented in the_Inset_.
Figure 4
Systematic functional analysis of AML samples based on SWISS-PROT database functional annotations for expressed genes. z statistics were calculated for each gene to describe the expression difference in that gene across sample groups. The plots show the cumulative distribution for the ranks of the genes in the functional category relative to all expressed genes. The tick marks at the top of the plots show the ranks of the individual genes; only those showing significant dysregulation (z scores below −1 or above +1) are indicated. (A) Twenty-three expressed genes involved in cell adhesion showed a shift to the right indicating up-regulation of genes in the AML compared with CD34+ samples (P = 0.010). (B) Twenty-three genes involved in apoptosis showed a shift to the left indicating down-regulation in AML+8 compared with AML-CN (P < 0.001).
Similar articles
- Impact of trisomy 8 on expression of genes located on chromosome 8 in different AML subgroups.
Schoch C, Kohlmann A, Dugas M, Kern W, Schnittger S, Haferlach T. Schoch C, et al. Genes Chromosomes Cancer. 2006 Dec;45(12):1164-8. doi: 10.1002/gcc.20380. Genes Chromosomes Cancer. 2006. PMID: 17001623 - Routine expression profiling of microarray gene signatures in acute leukaemia by real-time PCR of human bone marrow.
Sakhinia E, Faranghpour M, Liu Yin JA, Brady G, Hoyland JA, Byers RJ. Sakhinia E, et al. Br J Haematol. 2005 Jul;130(2):233-48. doi: 10.1111/j.1365-2141.2005.05594.x. Br J Haematol. 2005. PMID: 16029452 - Gene expression analysis reveals HOX gene upregulation in trisomy 8 AML.
Kok CH, Brown AL, Ekert PG, D'Andrea RJ. Kok CH, et al. Leukemia. 2010 Jun;24(6):1239-43. doi: 10.1038/leu.2010.85. Epub 2010 Apr 29. Leukemia. 2010. PMID: 20428200 No abstract available. - Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
Baldus CD, Bullinger L. Baldus CD, et al. Semin Oncol. 2008 Aug;35(4):356-64. doi: 10.1053/j.seminoncol.2008.04.006. Semin Oncol. 2008. PMID: 18692686 Review. - Trisomy 8 as the sole chromosomal aberration in acute myeloid leukemia and myelodysplastic syndromes.
Paulsson K, Johansson B. Paulsson K, et al. Pathol Biol (Paris). 2007 Feb;55(1):37-48. doi: 10.1016/j.patbio.2006.04.007. Epub 2006 May 11. Pathol Biol (Paris). 2007. PMID: 16697122 Review.
Cited by
- Gene dosage compensation: Origins, criteria to identify compensated genes, and mechanisms including sensor loops as an emerging systems-level property in cancer.
Bravo-Estupiñan DM, Aguilar-Guerrero K, Quirós S, Acón MS, Marín-Müller C, Ibáñez-Hernández M, Mora-Rodríguez RA. Bravo-Estupiñan DM, et al. Cancer Med. 2023 Dec;12(24):22130-22155. doi: 10.1002/cam4.6719. Epub 2023 Nov 21. Cancer Med. 2023. PMID: 37987212 Free PMC article. Review. - MYC dosage compensation is mediated by miRNA-transcription factor interactions in aneuploid cancer.
Acón M, Geiß C, Torres-Calvo J, Bravo-Estupiñan D, Oviedo G, Arias-Arias JL, Rojas-Matey LA, Edwin B, Vásquez-Vargas G, Oses-Vargas Y, Guevara-Coto J, Segura-Castillo A, Siles-Canales F, Quirós-Barrantes S, Régnier-Vigouroux A, Mendes P, Mora-Rodríguez R. Acón M, et al. iScience. 2021 Nov 8;24(12):103407. doi: 10.1016/j.isci.2021.103407. eCollection 2021 Dec 17. iScience. 2021. PMID: 34877484 Free PMC article. - Development of siRNA-Loaded Lipid Nanoparticles Targeting Long Non-Coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute Myeloid Leukemia.
Connerty P, Moles E, de Bock CE, Jayatilleke N, Smith JL, Meshinchi S, Mayoh C, Kavallaris M, Lock RB. Connerty P, et al. Pharmaceutics. 2021 Oct 14;13(10):1681. doi: 10.3390/pharmaceutics13101681. Pharmaceutics. 2021. PMID: 34683974 Free PMC article. - Gene-set distance analysis (GSDA): a powerful tool for gene-set association analysis.
Cao X, Pounds S. Cao X, et al. BMC Bioinformatics. 2021 Apr 21;22(1):207. doi: 10.1186/s12859-021-04110-x. BMC Bioinformatics. 2021. PMID: 33882829 Free PMC article. - Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT.
Baron F, Labopin M, Blaise D, Itälä-Remes M, Socié G, Forcade E, Yakoub-Agha I, Gorin NC, Esteve J, Nagler A, Mohty M. Baron F, et al. Bone Marrow Transplant. 2021 Feb;56(2):461-469. doi: 10.1038/s41409-020-01051-6. Epub 2020 Sep 4. Bone Marrow Transplant. 2021. PMID: 32887941
References
- Orkin S H. Curr Opin Cell Biol. 1995;7:870–877. - PubMed
- Tenen D, Hromas R, Licht J, Zhang D. Blood. 1997;90:489–519. - PubMed
- Wickremasinghe R, Hoffbrand A. Blood. 1999;93:3587–3600. - PubMed
- Heim S, Mitelman F. Cancer Cytogenetics. New York: Wiley; 1995.
- Byrd J C, Lawrence D, Arthur D C, Pettenati M J, Tantravahi R, Qumsiyeh M, Stamberg J, Davey F R, Schiffer C A, Bloomfield C D. Clin Cancer Res. 1998;4:1235–1241. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10 CA077658/CA/NCI NIH HHS/United States
- U10 CA031946/CA/NCI NIH HHS/United States
- GM58934/GM/NIGMS NIH HHS/United States
- CA09338/CA/NCI NIH HHS/United States
- P30 CA016058/CA/NCI NIH HHS/United States
- CA77658/CA/NCI NIH HHS/United States
- T32 CA009338/CA/NCI NIH HHS/United States
- CA31946/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical